journal article·2023-04Open access

A Bio‐Liposome Activating Natural Killer Cell by Illuminating Tumor Homogenization Antigen Properties

Xue Yang, Jiayi Bian, Zheng Wang, Mengning He, Ying Yang, Quanhao Li, Xinping Luo, Zhanwei Zhou, Jing Li, Shenghong Ju, Minjie Sun

Advanced Science· Volume 10· Issue 12

Abstract

Abstract Natural killer (NK) cell therapies, primarily based on chimeric antigen receptor NK cells (CAR‐NK), have been developed and applied clinically for therapeutic treatment of patients with mid‐to‐late‐stage tumors. However, NK cell therapy has limited efficacy due to insufficient antigen expression on the tumor cell surface. Here, a universal “illuminate tumor homogenization antigen properties” (ITHAP) strategy to achieve stable and controlled antigen expression on the surface of tumor cells using nanomedicine, thus significantly enhancing the immune recognizability of tumor cells, is described. The ITHAP strategy is used to generate bio‐liposomes (Pt@PL‐IgG) composed of intermingled platelet membranes and liposomes with NK‐activatable target antigen (IgG antibodies) and cisplatin pre‐drug. It is demonstrated that Pt@PL‐IgG successfully targets tumor cells using the autonomous drive of platelet membranes and achieves IgG implantation on tumor cells by utilizing membrane fusion properties. Moreover, it is shown that the Pt‐DNA complex combined with NK cell‐induced pyroptosis causes substantial interferon (IFN) secretion, thus providing a synthase‐stimulator of interferon genes (STING)‐IFN‐mediated positive immune microenvironment to further potentiate NK therapy. These results show that anchoring cancer cells with NK‐activatable target antigens is a promising translational strategy for addressing therapeutic challenges in tumor heterogeneity.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Immune Cell Function and Interaction · Phagocytosis and Immune Regulation · Immune cells in cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Natural Medicines Department of Pharmaceutics China Pharmaceutical University Nanjing 210009 P. R. China

Jiangsu Key Laboratory of Molecular and Functional Imaging Department of Radiology, Zhongda Hospital Medical School of Southeast University Nanjing 210009 P. R. China

Funding

Natural Science Foundation of Jiangsu Province · National Natural Science Foundation of China

References (52)

Show source-provided references
1. 10.1016/j.cell.2018.09.03510.1016/j.cell.2018.09.035 ↗
2. 10.1016/j.immuni.2019.12.01010.1016/j.immuni.2019.12.010 ↗
3. 10.1126/sciadv.abd271210.1126/sciadv.abd2712 ↗
4. 10.1038/s41590-020-0728-z10.1038/s41590-020-0728-z ↗
5. 10.1016/j.coi.2017.01.00310.1016/j.coi.2017.01.003 ↗
6. 10.1126/sciimmunol.aaz273810.1126/sciimmunol.aaz2738 ↗
7. 10.1038/icb.2017.610.1038/icb.2017.6 ↗
8. 10.3389/fimmu.2013.0007610.3389/fimmu.2013.00076 ↗
9. 10.1038/s41586-020-2071-910.1038/s41586-020-2071-9 ↗
10. 10.1126/science.aaz754810.1126/science.aaz7548 ↗
11. 10.1158/2159-8290.CD-13-098510.1158/2159-8290.CD-13-0985 ↗
12. 10.1016/j.cyto.2019.02.00110.1016/j.cyto.2019.02.001 ↗
13. 10.1182/blood-2020-14249410.1182/blood-2020-142494 ↗
14. Cichocki F. · Sci. Transl. Med. · 2020 · 12
15. Tang X. · Am. J. Cancer Res. · 2018 · 8 · 1083
16. 10.1158/1535-7163.MCT-12-069210.1158/1535-7163.MCT-12-0692 ↗
17. 10.1016/j.blre.2018.02.00410.1016/j.blre.2018.02.004 ↗
18. 10.1182/blood-2018-99-11897010.1182/blood-2018-99-118970 ↗
19. 10.1038/nature1262510.1038/nature12625 ↗
20. 10.1007/s10555-021-09957-310.1007/s10555-021-09957-3 ↗
21. 10.1016/j.cell.2019.08.03210.1016/j.cell.2019.08.032 ↗
22. 10.1158/0008-5472.CAN-13-256310.1158/0008-5472.CAN-13-2563 ↗
23. 10.1016/j.intimp.2019.10569510.1016/j.intimp.2019.105695 ↗
24. 10.1038/s41586-019-1054-110.1038/s41586-019-1054-1 ↗
25. 10.1158/2159-8290.CD-18-044210.1158/2159-8290.CD-18-0442 ↗
26. 10.1016/j.omto.2019.12.00610.1016/j.omto.2019.12.006 ↗
27. 10.1126/sciadv.abc437310.1126/sciadv.abc4373 ↗
28. 10.1016/j.nantod.2021.10110910.1016/j.nantod.2021.101109 ↗
29. 10.1021/acs.nanolett.9b0093410.1021/acs.nanolett.9b00934 ↗
30. 10.1038/nature1537310.1038/nature15373 ↗
31. 10.1038/s41467-021-22311-z10.1038/s41467-021-22311-z ↗
32. 10.1021/bi00435a01210.1021/bi00435a012 ↗
33. 10.1002/adma.20150428810.1002/adma.201504288 ↗
34. 10.1016/j.biomaterials.2018.01.01810.1016/j.biomaterials.2018.01.018 ↗
35. 10.1038/s41467-019-08290-210.1038/s41467-019-08290-2 ↗
36. 10.1073/pnas.121500610910.1073/pnas.1215006109 ↗
37. 10.1126/science.123245810.1126/science.1232458 ↗
38. 10.1016/j.immuni.2018.09.01610.1016/j.immuni.2018.09.016 ↗
39. 10.1016/j.biomaterials.2015.10.04610.1016/j.biomaterials.2015.10.046 ↗
40. 10.1002/ijc.2899710.1002/ijc.28997 ↗
41. 10.1016/j.actbio.2010.08.00310.1016/j.actbio.2010.08.003 ↗
42. 10.1002/smll.20120112910.1002/smll.201201129 ↗
43. 10.1158/1078-0432.CCR-10-073510.1158/1078-0432.CCR-10-0735 ↗
44. 10.1158/0008-5472.CAN-17-361410.1158/0008-5472.CAN-17-3614 ↗
45. 10.1038/s41551-020-0583-010.1038/s41551-020-0583-0 ↗
46. 10.1002/adfm.20200574710.1002/adfm.202005747 ↗
47. 10.3389/fimmu.2020.0061510.3389/fimmu.2020.00615 ↗
48. 10.1002/advs.20190259910.1002/advs.201902599 ↗
49. Tanyi J. L. · Sci. Transl. Med. · 2018 · 10
50. 10.3389/fimmu.2018.0305910.3389/fimmu.2018.03059 ↗
51. 10.1038/s41422-020-0324-710.1038/s41422-020-0324-7 ↗
52. 10.1021/acsnano.7b0812210.1021/acsnano.7b08122 ↗